Table 3.
Radiopharmaceutical therapy agents approved wordwide
| Radionuclides | Type | Agent | Targets | Indication |
|---|---|---|---|---|
| Radium-223 | α | [223Ra]RaCl2 | As a calcium mimic accumulating in bone554 | Prostate cancer bone metastases |
| Phosphorus-32 | β | [32P]Sodium orthophosphate | Major bone deposition69 | Palliation of bone pain due to metastases |
| Strontium-89 | β | [89Sr]SrCl2 | As a calcium mimic accumulating in bone69,70 | Prostate cancer bone metastases |
| Samarium-153 | β | [153Sm]Lexidronam | As a calcium mimic accumulating in bone71 | Relieving pain associated with bone metastasis |
| Lutetium-177 | β | [177Lu]Lu-PSMA-617 | PSMA | mCRPC |
| [177Lu]Lu-DOTA-TATE | SSTR | NETs | ||
| Yttrium-90 | β | [90Y]Resin microspheres | Selective internal radiation therapy | Hepatocellular carcinoma |
| [90Y]Glass microspheres | Selective internal radiation therapy | Hepatocellular carcinoma | ||
| [90Y]Y-DTPA-ibritumomab tiuxetan | CD20 | Non-Hodgkin’s follicular lymphoma | ||
| Iodine-131 | β | [131I]MIBG | Norepinephrine tansporter73 | NETs |
| [131I]Sodium iodinate | Sodium Iodide Symporter555 | Hyperthyroidism and thyroid carcinoma | ||
| [131I]Metuximab | CD147556 | Hepatocellular carcinoma | ||
| [131I]Tositumomab | CD20 | Non-Hodgkin’s follicular lymphoma |